Dietary Supplements — DSHEA and FDA's Limited Regulatory Authority

The Dietary Supplement Health and Education Act of 1994 (DSHEA) created a regulatory category that is neither food nor drug — and in doing so, sharply limited the FDA's authority to regulate the $60+ billion dietary supplement industry. For FDA's more rigorous drug approval process — where manufacturers must prove safety and efficacy before sale — see FDA drug approval. For the food safety framework that governs conventional food products, see food safety regulation. Under DSHEA, supplement manufacturers do not need to prove their products are safe or effective before selling them. Instead, the burden falls on FDA to prove a supplement is unsafe after it is on the market — the opposite of the drug approval model where manufacturers must demonstrate safety and efficacy before sale. DSHEA applies to vitamins, minerals, herbs, amino acids, enzymes, probiotics, and similar products sold in capsule, tablet, powder, or liquid form with claims related to health or nutritional support. The practical result: an estimated 80,000+ dietary supplement products are available to consumers with widely varying levels of scientific support for their claimed benefits and with quality that ranges from rigorously tested to nearly fraudulent. The law has been criticized by medical and public health researchers as a regulatory gap that allows ineffective or even dangerous products to reach consumers; the supplement industry defends it as protecting consumer access to health-promoting products from overly restrictive pharmaceutical-style regulation.

Current Law (2026)

What Is a Dietary Supplement?

Under 21 U.S.C. § 321(ff), a dietary supplement is a product intended to supplement the diet that contains one or more:

• Vitamins (A, C, D, E, K, B vitamins)
• Minerals (calcium, magnesium, iron, zinc)
• Herbs or botanicals (echinacea, St. John's Wort, ginkgo biloba)
• Amino acids (glutamine, lysine, branched-chain amino acids)
• Dietary substances for use to supplement the diet by increasing total dietary intake
• Concentrates, metabolites, constituents, or extracts of any of the above

Products must be intended for ingestion in pill, capsule, tablet, powder, or liquid form and must be labeled as a dietary supplement. They cannot be represented as a conventional food or sole item of a meal.

Key exclusions: A product that is approved as a drug before being marketed as a supplement generally cannot be sold as a supplement (this has been controversial — FDA used this rule to block CBD products from supplement sales after CBD appeared in an approved drug, Epidiolex, though enforcement has been inconsistent).

The Pre-Market vs. Post-Market Distinction

The most consequential feature of DSHEA is the reversal of the safety burden:

Drugs: Manufacturer must demonstrate safety and efficacy to FDA's satisfaction before market entry. FDA can block an unsafe drug from reaching consumers.

Dietary supplements: Manufacturer may market the product without prior FDA review. FDA must gather evidence that a product poses an "unreasonable risk" and then take enforcement action — a process that can take years after consumer harm is identified.

This means FDA typically learns about problems through:

• Adverse event reports (mandatory for serious adverse events since 2006 under 21 U.S.C. § 379aa-1)
• Consumer and healthcare provider voluntary MedWatch reports
• Poison control center data
• Published research or media investigations

By the time FDA acts, consumers may have been harmed for months or years.

New Dietary Ingredient (NDI) Notification

For ingredients not marketed in the U.S. before October 15, 1994 (the DSHEA enactment date), manufacturers must submit a New Dietary Ingredient (NDI) notification to FDA at least 75 days before marketing (21 U.S.C. § 350b). The notification must include:

• The identity of the ingredient
• History of use or other evidence of safety
• The manufacturer's basis for concluding the ingredient will "reasonably be expected to be safe"

FDA does not approve or deny NDI notifications — it simply acknowledges receipt and may raise safety objections. If FDA objects, the manufacturer can address the concerns, reformulate, or proceed with marketing and risk enforcement action. NDI compliance is widely seen as inadequate — a large portion of novel supplement ingredients reach market without proper NDI notification.

Allowed Claims vs. Prohibited Claims

The claims a supplement can make are strictly defined:

Structure/Function Claims (Allowed) Claims that describe the role of a nutrient or ingredient in affecting the structure or function of the body:

• "Calcium builds strong bones"
• "Fiber maintains bowel regularity"
• "Antioxidants maintain cell integrity"
• "This product supports immune health"

These claims must be truthful and not misleading, must be accompanied by the disclaimer "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease," and must be notified to FDA within 30 days of first marketing.

Disease Claims (Prohibited without drug approval) Claims that a product diagnoses, cures, treats, mitigates, or prevents a specific disease cross the line from supplement into drug territory:

• "Reduces blood pressure" — prohibited (implies treatment of hypertension)
• "Prevents type 2 diabetes" — prohibited
• "Treats depression" — prohibited

When a supplement makes disease claims, FDA can regulate it as an unapproved new drug — but enforcement is resource-intensive and FDA only pursues the most egregious cases.

Good Manufacturing Practices (GMPs)

Since 2010, dietary supplement manufacturers must comply with Current Good Manufacturing Practice regulations at 21 CFR Part 111 — the FDA's most detailed regulatory requirement for the supplement industry. The regulation covers every step of manufacturing, from raw material receipt through finished product distribution:

Ingredient controls (Subpart G): Every raw ingredient received must be tested to confirm its identity — not assumed based on the supplier's certificate of analysis. If a company labels a capsule as containing 500 mg of ginkgo biloba extract, Part 111 requires that the actual ingredient be tested against a verified specification confirming it is ginkgo (not filler, not a different botanical, not the right plant but wrong part). Purity testing (no heavy metals, pesticides, microbiological contaminants above limits), potency testing (active compounds at stated levels), and composition testing (correct blend ratios) are all required. Components that fail specifications cannot be used.

Production and process controls (Subparts E, F, K): Manufacturers must develop and follow a Master Manufacturing Record (MMR) for each product — the complete formula and manufacturing instructions. Every batch of production must generate a Batch Production Record (BPR) showing that the batch was made in conformance with the MMR. Deviations from the MMR must be documented and investigated. This creates a paper trail that FDA inspectors audit during facility inspections.

Laboratory operations (Subpart J): Testing must be conducted by qualified laboratory personnel using validated test methods. Equipment must be calibrated on schedule. The lab must be kept separate from manufacturing areas to prevent contamination. Out-of-specification laboratory results must be investigated — the answer is not to simply retest until a passing result is obtained.

Complaint handling and returned supplements (Subparts N, O): Companies must maintain a written record of every consumer complaint received and investigate any complaint alleging a serious adverse event. Complaints that could relate to a product quality issue (wrong color, unexpected smell, adverse health effect) must be reviewed by a qualified person. Products returned from distribution must be quarantined and evaluated before being destroyed or reintroduced into inventory.

Quality control unit (Subpart F): An independent quality control unit — separate from production — must approve every finished batch before distribution. The QC unit may reject batches that fail specifications even if production management wants to release them. This independence requirement is one of the most frequently cited areas of non-compliance in FDA 483 inspection observations.

Key provisions:

• § 111.75 — Specification requirements: each ingredient and finished product must have written specifications covering identity, purity, strength, composition, and limits for contamination
• § 111.95 — Master manufacturing record: must be maintained for each unique formulation including every component used, weight/measure, manufacturing processing steps, equipment, packaging, labeling, and specifications for finished batch
• § 111.255–111.260 — Returned supplements: returned products must be quarantined and assessed for fitness; if safety is in doubt, the product must be destroyed
• § 111.570 — Records retention: all GMP records must be retained for at least one year beyond the product's shelf life or at least two years beyond the date of sale

The gap: GMPs address manufacturing quality but not safety or efficacy. A supplement that is perfectly manufactured — pure, correctly labeled — can still be biologically ineffective or harmful. Third-party testing organizations (NSF International, USP, Informed Sport, ConsumerLab) fill this gap partially by testing products against label claims, but their certification is voluntary. FDA's enforcement of GMP requirements has been significant but uneven — small manufacturers and contract manufacturers are the most common subjects of warning letters for GMP violations.

How It Affects You

If you take dietary supplements: The FDA disclaimer on supplement labels — "This statement has not been evaluated by the Food and Drug Administration" — is not boilerplate. It means the product you are taking has not been reviewed by any federal agency for safety or efficacy before sale. For commonly used vitamins and minerals with long safety records, this is generally a low concern. For proprietary blends, newer botanical ingredients, weight loss supplements, sexual enhancement products, or performance enhancers, the risk of undisclosed active ingredients, contamination, or harm is meaningfully higher. The FTC's Operation Fake Cures and FDA's Tainted Supplements database document hundreds of supplements found to contain undisclosed pharmaceutical ingredients, controlled substances, or dangerous compounds. Check the NIH Office of Dietary Supplements (ods.od.nih.gov) for evidence-based fact sheets on specific supplements; look for third-party certifications (NSF, USP) that verify label accuracy and manufacturing quality.

If you are managing a health condition and considering supplements: Supplements can interact with prescription drugs. St. John's Wort reduces the effectiveness of birth control pills, HIV medications, blood thinners, and many other drugs. Ginkgo, fish oil, and vitamin E have anticoagulant effects that matter before surgery. Calcium can interfere with thyroid medication absorption. Your pharmacist (who can see your full medication list) is the right person to check supplement-drug interactions — better than a general internet search. The Natural Medicines database (naturalmedicines.therapeuticresearch.com), available through many public libraries, provides evidence ratings for specific supplements and comprehensive interaction data.

If you are considering weight loss, sexual enhancement, or sports performance supplements: These three categories account for a disproportionate share of FDA enforcement actions. FDA's Tainted Supplements database (fda.gov/consumers/health-fraud-scams/tainted-supplements) lists hundreds of products found to contain undisclosed prescription drug ingredients — weight loss supplements containing sibutramine (withdrawn from the market for cardiovascular risk), sexual enhancement products containing sildenafil (Viagra), and sports supplements containing designer anabolic steroids. These are not theoretical risks. If a product produces dramatic results quickly, it is more likely adulterated than magic.

If you are a healthcare provider: Ask patients about supplement use at every medication reconciliation. Supplement use is often not disclosed because patients do not consider supplements "medicines." The most clinically significant interactions in your patient population depend on what you treat — anticoagulation patients and botanicals, transplant patients and St. John's Wort, thyroid patients and calcium timing, cancer patients and antioxidants during chemotherapy (which may reduce treatment efficacy). Report adverse events from supplements to MedWatch (fda.gov/safety/medwatch); FDA's post-market surveillance depends heavily on voluntary healthcare provider reporting.

The Legislative Debate

DSHEA has been controversial since enactment. Critics argue:

• FDA lacks resources to monitor 80,000+ products for safety after market entry
• NDI notification is widely ignored or circumvented
• Structure/function claim line is easy to blur in marketing
• Harms accumulate before FDA can act

Industry and libertarian proponents argue:

• Consumer choice in health decisions should be protected from over-regulation
• Most supplements have long safety records
• Drug-level approval would eliminate products that are safe but lack drug-level proof of efficacy
• State attorneys general and FTC provide additional consumer protection

Reform proposals that have circulated but not passed include mandatory pre-market notification for all new products, mandatory listing of all products marketed, expanded NDI enforcement, and authority for FDA to order recalls without going to court.

Recent Developments

• CBD and supplements: FDA has taken the position that CBD (cannabidiol), as an approved drug ingredient (Epidiolex), cannot be legally marketed as a dietary supplement under current law. FDA issued a call for congressional action to establish a regulatory framework for CBD; as of 2026, a definitive framework has not been enacted, leaving CBD supplements in a regulatory gray zone with inconsistent enforcement
• FTC enforcement: The FTC (not FDA) is often the more active enforcer of false supplement advertising claims under its authority over deceptive advertising practices; FTC has pursued major cases against supplement companies making unsupported disease claims
• Sports supplement stimulants: FDA has taken enforcement action against supplements containing DMAA, DMHA, and other stimulants not proven safe as dietary ingredients, with mixed success in litigation
• Proposed mandatory listing: FDA has supported legislation requiring all supplement products to be listed with FDA (with basic ingredient information) before sale — a minimum-level registry that does not require safety review but would let FDA know what products exist on the market; no enacted legislation as of 2026